Literature DB >> 17611020

Concomitant DDX1 and MYCN gain in neuroblastoma.

Raffaella Defferrari1, Gian Paolo Tonini, Massimo Conte, Filippo Papio, Angela Rita Sementa, Alexander Valent, Francesca Schena, Patrizia Perri, Katia Mazzocco.   

Abstract

DDX1, a gene mapping to the 2p24 region, has been observed to be co-amplified with MYCN in neuroblastoma. Co-amplification of the DDX1 gene is a consequence of the short physical distance between the two genes. Recently, it has been found that neuroblastoma cells can show a low increase in MYCN gene copy number, defined as MYCN gain. We studied 13 neuroblastomas with MYCN gain to evaluate the status of the DDX1 gene. We investigated DDX1/MYCN gain by double-colour FISH on interphase nuclei. All cases showed concomitant low extra copy number of DDX1 and MYCN. Heterogeneous distribution of nuclei displaying DDX1/MYCN gain was observed in almost all tumours, suggesting a clonal evolution of cells with DDX1/MYCN gain. This is the first report that shows DDX1 co-gained with MYCN in neuroblastoma and indicates that DDX1 over-representation is closely associated with an increase in MYCN copy number in neuroblastoma cells. Since DDX1 has already been found co-amplified with MYCN, DDX1 gain seems to be a further rearrangement due to the physical proximity of the two genes. Moreover, all patients with DDX1/MYCN gain show a good overall survival but a high frequency of adverse events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611020     DOI: 10.1016/j.canlet.2007.05.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma.

Authors:  Nicholas Ho; Hui Peng; Chelsea Mayoh; Pei Y Liu; Bernard Atmadibrata; Glenn M Marshall; Jinyan Li; Tao Liu
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

2.  Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Authors:  Eva Villamón; Ana P Berbegall; Marta Piqueras; Irene Tadeo; Victoria Castel; Anna Djos; Tommy Martinsson; Samuel Navarro; Rosa Noguera
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

3.  Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy.

Authors:  Chantal Hoi Yin Cheung; Chia-Lang Hsu; Chao-Yin Tsuei; Tzu-Ting Kuo; Chen-Tsung Huang; Wen-Ming Hsu; Yun-Hsien Chung; Hsin-Yi Wu; Cheng-Chih Hsu; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Cell Death Dis       Date:  2019-10-17       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.